IP Library Granted Patent US 9,415,046
Granted Patent B2
US 9,415,046 · App. 13/496,009 · Granted Aug 16, 2016

Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods

Inventors: Wajahat Z. Mehal (Guilford, CT); Themis Kyriakides (Branford, CT)
Assignee: YALE UNIVERSITY
A61K31/495A61K9/0024A61K31/47A61K31/4706A61K31/496A61K31/60A61K31/612A61K31/7088A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,415,046
App. No.
13/496,009
Granted
Aug 16, 2016
Kind
B2
Abstract

The present invention relates, inter alia, to methods and compositions for regulating the host response to biomaterials, including inhibiting inflammation from and rejection of biomaterials using salicylate compounds and/or TLR7/TLR9 antagonists as described herein.

Claims (20)

1. A method for reducing, inhibiting or reducing the likelihood of foreign body reaction associated with an implant which produces foreign body reaction in a human patient by increasing proinflammatory cytokines by upregulating a TLR 7/TLR9/NALP3 inflammasome pathway comprising administering to said patient with said implant a pathway inhibiting effective amount of a sustained release composition consisting essentially of a salicylate compound according to the chemical structure:

where R is H or a C 2 -C 10 acyl group, or

a pharmaceutically acceptable salt thereof to said patient, wherein the sustained release administration of said salicylate compound increases the residence time of said implant in said patient by reducing inflammation and scarring associated with said implant and wherein said sustained release composition continuously releases said salicylate in effective amounts.

2. The method according to claim 1 wherein said reduction in the foreign body reaction reduces the likelihood of rejection of said implant by said patient.

3. The method according to claim 1 wherein said administration also reduces one or more of deposition of cells at the site of the implant, pain- and/or swelling at the site of the implant, tenderness at the site of the implant, and infection at the site of the implant in the patient.

4. The method according to claim 1 wherein said administration also reduces deposition of cells at the site of the implant.

5. The method according to claim 4 wherein said cells are neutrophils or macrophages.

6. The method according to claim 1 wherein said administration also reduces pain and/or swelling at the site of the implant.

7. The method according to claim 2 wherein said administration also reduces tenderness at the site of the implant.

8. The method according to claim 2 wherein said administration also reduces infection at the implant.

9. The method according to claim 1 wherein said implant is a pacemaker, a cochlear implant, a subcutaneous drug delivery device, an implantable pill, a drug-eluting stent, a surgical clip, a suture, a surgical mesh, a breast implant, a glucose or insulin sensor, an artificial heart-valve, a bio-implant implanted to replace damaged tissue, a dental implant, an orthopedic implant or a prosthetic device.

10. The method according to claim 1 wherein said implant comprises a biomaterial selected from the group consisting of polymeric materials, metals and ceramics.

11. The method according to claim 9 wherein said implant comprises steel, titanium, silicone, polyester or polypropylene.

12. The method according to claim 1 wherein R is H or a C 2 acyl group, or a pharmaceutically acceptable salt thereof.

13. The method according to claim 1 where R is a C 2 acyl group or a pharmaceutically acceptable salt thereof.

14. The method according to claim 3 wherein R is H or a C 2 acyl group, or a pharmaceutically acceptable salt thereof.

15. The method according to claim 3 where R is a C 2 acyl group or a pharmaceutically acceptable salt thereof.

16. The method according to claim 12 wherein said implant is a pacemaker, a cochlear implant, a subcutaneous drug delivery device, an implantable pill, a drug-eluting stent, a surgical clip, a suture, a surgical mesh, a breast implant, a glucose or insulin sensor, an artificial heart-valve, a bio-implant implanted to replace damaged tissue, a dental implant, an orthopedic implant or a prosthetic device.

17. The method according to claim 12 wherein said implant comprises a biomaterial selected from the group consisting of polymeric materials, metals and ceramics.

18. The method according to claim 17 wherein said implant comprises steel, titanium, silicone, polyester or polypropylene.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jan 29, 2013
From: YALE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029717/0698 →
Continuity (3)
Provisional Application 61281823 · Nov 23, 2009
Provisional Application 61277798 · Sep 29, 2009
Related Publication 20120225931A1 · Sep 6, 2012